Supreme Pharmaceuticals, Inc. (SL/SPRWF)

logo-supreme-whiteSupreme Pharmaceuticals, Inc, otherwise known as Supreme Pharma and Bioscience, is a Canadian biomedicine company that formerly operated as a mining company. Its current focus is on medical cannabis. For this, the company has a greenhouse in Ontario and is preparing to sell its products online.

The Supreme Greenhouse, located in Kincardine, Ontario, is the flagship operation of Supreme Pharama. The facility covers some 342,000 square feet, of which 280,000 square feet will be for growing the cannabis plants and over 6,000 square feet will be for R&D. One facility feature that Supreme emphasizes is that it will use natural sunlight augmented by state-of-the-art equipment. This is in contrast to the indoor growing that many other marijuana companies do.

Preparations for Supreme Pharma’s online selling are now underway. The company has put up an online marijuana shop and created the customer discount program CanAssist.

Supreme Pharmaceuticals entered the marijuana industry by acquiring the cannabis company Advanced Medical Marijuana Canada (AMMCan). AMMCan has been preapproved by Health Canada to produce and distribute a maximum of 24,000 kilograms of marijuana per year. As a wholly owned subsidiary of Supreme Pharma, AMMCan is now Supreme Medical Marijuana (AMMCan Supreme).

Prior to cannabis-growing, Supreme Pharma operated various businesses since as far back as 1979, when it was founded. Among its former names are Sonar Energy Company, US Platinum, and Universal Energy Corp. It became Supreme Resources, Ltd in 2007, operating as a junior mining firm that explored base and precious metals in BC. In March 2014, pursuing its new direction, it finally became Supreme Pharmaceuticals, Inc.

Today, Supreme Pharmaceuticals is listed as SL on the Canadian Stock Exchange, and as SPRWF on the US OTC markets. Its market cap is at USD 22.91 M.

The top executive at Supreme Pharma is Chairman, CEO, and President David Stadnyk, alongside Executive VP Brayden R. Sutton and Production Advisor Thaddeus Conrad. They are joined by AMMCan executives like CEO Peter M. Herburger, Medical Director Dr. Kenneth Adams, and Director of Operations John Fowler.

Supreme Pharmaceuticals, Inc.

Suite #430
580 Hornby St
Vancouver, BC
V6C 3B6

Phone: (604) 674-2191
Email: info@supreme.ca
Website: https://www.supreme.ca/


Yahoo! Finance: SPRWF News

Latest Financial News for SPRWF

Supreme Cannabis Closes Acquisition Of Blissco Cannabis

Supreme Cannabis Company Inc (OTC: SPRWF ) announced that the Supreme Court of British Columbia has released a final order approving previously announced agreement to acquire Blissco Cannabis Corp. (OTC: ...

Supreme Cannabis to Close Acquisition of Premium Wellness Brand and Extraction Company Blissco

Blissco to expand Supreme Cannabis' portfolio of premium cannabis brands into the wellness category. Will provide in-house extraction capabilities for other Supreme Cannabis brands, including 7ACRES. Will expand Supreme Cannabis' product portfolio to include CBD and THC wellness products and pre-rolls.

Blissco Cannabis Corp. Announces 99.28% Shareholder Approval of Arrangement with The Supreme Cannabis Company, Inc.

Blissco Cannabis Corp. (the Company or Blissco) (CSE:BLIS) (HSTRF) (FRA:GQ4B) is pleased to announce that, at the special meeting of shareholders of Blissco (Blissco Shareholders) held today (the Meeting), Blissco Shareholders voted in favour of a special resolution (the Arrangement Resolution) to approve the previously announced plan of arrangement (the Arrangement) between Blissco and The Supreme Cannabis Company, Inc. (Supreme Cannabis) (FIRE.TO) (SPRWF) (53S1.F). Subject to the terms and conditions of an arrangement agreement (the Arrangement Agreement) between Blissco and Supreme Cannabis dated May 16, 2019, Supreme Cannabis will acquire all of the issued and outstanding common shares of Blissco (Blissco Shares) not already owned by Supreme Cannabis.

Can Vaping Growth Help Investors Extract More Value From Aphria Stock?

Of the multiple positive catalysts should fuel Aphria Inc (NYSE:APHA) in the months ahead, the most intriguing one is is vaping, or using a vaporizer to get the desired effect from cannabis use. My InvestorPlace colleague Will Healy pointed out some of these catalysts in his June 6 article, when APHA stock was trading at more than 50% below its 52-week high.Source: Shutterstock InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe next day, Aphria announced that it had entered into a supply agreement for the Canadian market with San Francisco-based Pax Labs, a leader in the manufacture and sale of vaporizers. In the U.S. alone, Pax has sold more than 500,000 Era vaporizers to date with plenty of growth expected in the months and years ahead. "As Aphria continues to drive the evolution of the industry, we are thrilled to partner with a technology leader like PAX to provide a new avenue for consumers to integrate cannabis into their lives," said Irwin Simon, interim CEO of Aphria. "We are excited to bring our premium cannabis extracts from Solei, RIFF and our flagship medical cannabis brand, Aphria, to the PAX Era device and platform." Vaping is Going to Be Big in CanadaThe vaping market in Canada is expected to be significant. Aphria estimates that vapes and concentrates will account for up to 30% of the entire adult-use market by 2021. The great thing about vaping, from Aphria's perspective, is that concentrates provide a much higher margin than dried cannabis. * 7 Stocks to Buy for a Dovish Fed Statistics show that U.S. use of vape products is growing, while the use of dried flower is slowing. In Colorado, the use of vape products increased tremendously over three years. In 2014, vape products accounted for 12% of the legal market. By 2017, that number had grown to 23%. Meanwhile, over the same three years, the use of dried flower dropped by 12 percentage points to 54% of the market. Between edibles, concentrates, and infused drinks, the cannabis industry is moving away from the dried flower to an industry filled with choice. The fact that Aphria is partnering with one of the premier vape companies is a sign that Simon understands the importance of moving beyond supplying dried buds. APHA Is Not AloneThat only downside from Aphria's announcement is that PAX pick three other Canadian cannabis producers to help sell its product: Aurora Cannabis (NYSE:ACB), OrganiGram (NASDAQ:OGI), and Supreme Cannabis (OTCMKTS:SPRWF). However, the fact that Aphria is near completion of it $55 million Extraction Centre of Excellence in Leamington, Ontario, makes this concern far less of an issue. That's because when completed, Aphria will have annual extraction capacity of 200,240 kilograms, making it one of the largest extractors in Canada. Currently, analysts haven't factored Aphria's extraction facility into their valuation models. Once the facility is running, and products are available for sale in late December or early in 2020, Aphria stock is going to be far more attractive to investors than it is today. Bottom Line on Aphria StockIn May, I highlighted the pros and cons of the regime change at Aphria. As I stated, it's hard to know if Irwin Simon's the right person for the job. While his work at Hain Celestial (NASDAQ:HAIN) was at times exceptional, in recent years he did little to impress investors, eventually stepping down as CEO in June 2018. * The Top 8 Tech Stocks of 2019 (So Far) Joining the Aphria Inc board in December as chairman, Simon was appointed interim CEO on March 1 after former boss Vic Neufeld retired in January. Since then, Simon's made a few management changes to put his own stamp on the company. The PAX announcement is a sign Simon might be sticking around as the permanent CEO. If the board didn't have confidence in him, this kind of deal probably wouldn't have happened. While not completely sold on Simon, the PAX deal in combination with the completion of the extraction plant, suggests investors aren't giving Aphria stock its due.Aggressive investors ought to consider buying this potential growth and value play. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Top Small-Cap Stocks Of 2019 * Critical Levels to Watch in 7 Marijuana Stocks * 5 Smaller Cloud Stocks That Have Plenty of Potential Compare Brokers The post Can Vaping Growth Help Investors Extract More Value From Aphria Stock? appeared first on InvestorPlace.

Supreme Cannabis, Wiz Khalifa's Kush Enterprises Canada Launch Cannabis Oil

Supreme Cannabis Company Inc (OTC: SPRWF) on Tuesday launched a premium cannabis oil in partnership with Khalifa Kush Enterprises Canada. The KKE Oil is the first product under the KKA brand line developed under the partnership between Supreme Cannabis Company and rapper Wiz Khalifa's Khalifa Kush Enterprises Canada. It uses Sensi Star strain developed by 7ACRES, a wholly-owned subsidiary of Supreme Cannabis.